Filtered By:
Specialty: Urology & Nephrology
Source: American Journal of Nephrology
This page shows you your search results in order of date.
Order by Relevance | Date
Total 67 results found since Jan 2013.
Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis
CONCLUSION: Finerenone produces similar cardiorenal benefits in Asian and non-Asian patients.PMID:37708857 | DOI:10.1159/000532102
Source: American Journal of Nephrology - September 14, 2023 Category: Urology & Nephrology Authors: Daisuke Koya Stefan D Anker Luis M Ruilope Peter Rossing ZhiHong Liu Byung Wan Lee Chien-Te Lee Charlie Scott Peter Kolkhof Robert Lawatscheck Lili Wang Amer Joseph Bertram Pitt FIDELIO-DKD Investigators Source Type: research
Association of intradialytic hypertension with future cardiovascular events and mortality in hemodialysis patients: effects of ambulatory blood pressure
CONCLUSIONS: IDHTN patients had higher risk for mortality and cardiovascular outcomes but this risk is at least partly confounded by the elevated BP levels during the interdialytic period.PMID:37302385 | DOI:10.1159/000531477
Source: American Journal of Nephrology - June 11, 2023 Category: Urology & Nephrology Authors: Fotini Iatridi Marieta P Theodorakopoulou Antonios Karpetas Vasiliki Sgouropoulou Areti Georgiou Eleni Karkamani Artemios Karagiannidis Aikaterini Papagianni Pantelis A Sarafidis Source Type: research
Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients With Chronic Kidney Disease and Renal Anemia
Am J Nephrol. 2023 May 16. doi: 10.1159/000531084. Online ahead of print.ABSTRACTRenal anemia is treated with erythropoiesis-stimulating agents (ESA), even though epoietin alfa and darbepoietin increase the risk of cardiovascular death and thromboembolic events, including stroke. Hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD) inhibitors have been developed as an alternative to ESAs, producing comparable increases in hemoglobin. However, in advanced chronic kidney disease, HIF-PHD inhibitors can increase the risk of cardiovascular death, heart failure and thrombotic events to a greater extent than that with ES...
Source: American Journal of Nephrology - May 26, 2023 Category: Urology & Nephrology Authors: Milton Packer Source Type: research
Proteinuria and Risk for Heart Failure in 55,191 Patients Having History of Cancer
We examined the association of proteinuria with the risk for heart failure (HF) and other cardiovascular disease (CVD) events in patients with prior history of breast, colorectal, or stomach cancer using a nationwide population-based database.METHODS: We conducted this retrospective observation study using the JMDC Claims Database and analyzed 55,191 patients with prior history of breast, colorectal, or stomach cancer. The median age was 54 (48-60) years, and 20,665 participants (37.4%) were men. Using urine dipstick data at baseline, 3,945 and 1,521 participants were categorized as having trace and positive proteinuria, r...
Source: American Journal of Nephrology - December 21, 2022 Category: Urology & Nephrology Authors: Yuta Suzuki Hidehiro Kaneko Akira Okada Katsuhito Fujiu Nobuaki Michihata Taisuke Jo Norifumi Takeda Hiroyuki Morita Kentaro Kamiya Atsuhiko Matsunaga Junya Ako Koichi Node Masaomi Nangaku Hideo Yasunaga Issei Komuro Source Type: research
Utility of CHA2DS2-VASc Score to Predict Mid-Term Clinical Outcomes in Hemodialysis Patients
CONCLUSION: The CHA2DS2-VASc score is a valuable predictor of 3-year all-cause and CVD mortality in incident HD patients.PMID:35259747 | DOI:10.1159/000522225
Source: American Journal of Nephrology - March 8, 2022 Category: Urology & Nephrology Authors: Aiko Okubo Toshiki Doi Kenichi Morii Yoshiko Nishizawa Kazuomi Yamashita Kenichiro Shigemoto Sonoo Mizuiri Koji Usui Michiko Arita Takayuki Naito Takao Masaki Source Type: research
